BBIO
BridgeBio Pharma, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- May 27 ▲ BridgeBio announced FDA acceptance of its NDA with Priority Review f…
- Jun 3 Canaccord Genuity initiates
- Jun 22 to Jun 24 ▼ 3 days of insider sells: $3.1M by 2 insiders, avg $69.73
- Jun 28 ▲ BridgeBio announced positive Phase 3 PROPEL 3 results for oral infig…
- Jun 30 ▲ 3 funds open new positions (13F)
- Jul 9 ▼ 2 insiders sell $14.6M at $88.07
- Jul 30 ▼ 1 insider sell $160.1K at $80.06
- Aug 18 to Aug 19 ▼ 2 days of insider sells: $3.7M by 1 insider, avg $82.86
- Sep 17 ▼ 1 insider sell $690.8K at $69.08
- Oct 27 to Nov 2 ▲ 2 buys: Gilbert Cisneros bought $1,001 - $15,000, last disclosed Nov 11
- Oct 30 ▼ 1 insider sell $145.7K at $72.85
- Nov 6 Activist stake: BridgeBio Pharma Reports Inducement Grants under Nasdaq Li…
Signal stack
Where each data set points today.
- InsidersBEARISH
5 insiders sold $22.4M.
- InstitutionsMIXED
Q2 2026: 48 added (3 new), 34 trimmed or exited. Largest new: Point72 Asset Management, $113.6M, Qube Research & Technologies $54.2M.
- AnalystsBULLISH
26 of 29 rate it Buy or better.
- Short sellersSTEADY
Short interest +4.2% to 20.85M shares. 7.1 days to cover, ≈10.7% of shares.
- TrendUPTREND
10% above its 50-day average.
- SocialQUIET
No Reddit mentions this week. Last mention Oct 29.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| BlackRock, Inc. | TRIM | $766.2M |
| WELLINGTON MANAGEMENT GROUP LLP | DOUBLED | $395.4M |
| D. E. Shaw & Co., Inc. | ADD | $270.6M |
| GEODE CAPITAL MANAGEMENT, LLC | TRIM | $254.7M |
| JANE STREET GROUP, LLC | ADD | $218.5M |
| JPMORGAN CHASE & CO | ADD | $173.2M |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | DOUBLED | $167.7M |
| PRICE T ROWE ASSOCIATES INC /MD/ | TRIM | $128.6M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
29 analysts| Date | Firm | Rating |
|---|---|---|
| Nov 13, 2026 | Morgan Stanley MAINTAIN | Overweight |
| Nov 2, 2026 | Canaccord Genuity MAINTAIN | Buy |
| Oct 30, 2026 | TD Cowen MAINTAIN | Buy |
| Oct 30, 2026 | Morgan Stanley MAINTAIN | Overweight |
| Oct 21, 2026 | Morgan Stanley MAINTAIN | Overweight |
| Oct 19, 2026 | Citigroup MAINTAIN | Neutral |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Apuli Maricel Chief Accounting Officer Oct 30, 2026 | SELL | $145.7K |
Kumar Neil Chief Executive Officer Sep 17, 2026 | SELL | $601.9K |
Kumar Neil Chief Executive Officer Sep 17, 2026 | SELL | $89.0K |
Kumar Neil Chief Executive Officer Aug 19, 2026 | SELL | $152.4K |
Kumar Neil Chief Executive Officer Aug 19, 2026 | SELL | $679.3K |
Kumar Neil Chief Executive Officer Aug 19, 2026 | SELL | $8.6K |
Kumar Neil Chief Executive Officer Aug 18, 2026 | SELL | $154.2K |
Kumar Neil Chief Executive Officer Aug 18, 2026 | SELL | $1.2M |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | -$0.37 | -$0.62–-$0.15 | -2.1% | $338.1M |
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026Washington
SecBot reports
23 filings · 15 press releases · 4 bullish · 2 bearish · 5 mixed · 12 neutral- NEUTRAL SC 13G/ANov 12, 2026
Farallon Capital Management filed an amended Schedule 13G disclosing a 7.3% passive stake in…
Monitor for any future conversion to a 13D filing, which would signal activist intent. The increase by a passive holder is routine, but the size (7.3%) gives Farallon significant influence if it…
- BULLISH INST-CLUSTERNov 9, 2026
In Q3 2026, 13 institutional investors accumulated $112.8M in net new BBIO positions, led by…
The cluster is dominated by active asset managers (Citigroup, Candriam, Aberdeen, Fiera Capital) with no passive/index fund participation, giving the signal higher conviction. Monitor the upcoming…
- NEUTRAL PRESS RELEASENov 6, 2026
BridgeBio Pharma granted 147,578 restricted stock units to 80 new employees as an inducement…
This is a routine inducement grant for new hires with no immediate trading implications. Monitor future filings for any larger equity issuances or changes in share count.
- BULLISH 8-KOct 29, 2026
BridgeBio reported Q3 2026 total revenues of $353.2M, up 193% YoY from $120.7M, driven by $253.2M…
The company is approaching three binary PDUFA catalysts over the next seven months, with BBP-418 for LGMD2IR9 just 29 days away. Attruby's accelerating commercial trajectory and the $1.5B cash…
All BBIO filing & press-release reports (38)
- SC 13G/A reportNov 12, 2026
- INST-CLUSTER reportNov 9, 2026
- PRESS-RELEASE reportNov 6, 2026
- 8-K reportOct 29, 2026
- PRESS-RELEASE reportOct 29, 2026
- SC 13G reportOct 27, 2026
- PRESS-RELEASE reportOct 22, 2026
- 8-K reportOct 13, 2026
- PRESS-RELEASE reportOct 6, 2026
- PRESS-RELEASE reportOct 5, 2026
- PRESS-RELEASE reportOct 5, 2026
- PRESS-RELEASE reportSep 18, 2026
- 8-K reportAug 31, 2026
- PRESS-RELEASE reportAug 26, 2026
- INST-CLUSTER reportAug 22, 2026
- 8-K reportAug 17, 2026
- PRESS-RELEASE reportAug 13, 2026
- 8-K reportAug 10, 2026
- PRESS-RELEASE reportAug 10, 2026
- CLUSTER reportJul 13, 2026
- PRESS-RELEASE reportJun 28, 2026
- 144 reportJun 24, 2026
- PRESS-RELEASE reportJun 22, 2026
- PRESS-RELEASE reportMay 27, 2026
- CLUSTER reportMay 26, 2026
- 144 reportMay 21, 2026
- CLUSTER reportMay 19, 2026
- PRESS-RELEASE reportMay 12, 2026
- PRESS-RELEASE reportMay 11, 2026
- S-3ASR reportMay 7, 2026
- PRESS-RELEASE reportMay 7, 2026
- PRESS-RELEASE reportMay 6, 2026
- PRESS-RELEASE reportMay 5, 2026
- DEFA14A reportApr 24, 2026
- CLUSTER reportMar 10, 2026
- CLUSTER reportMar 10, 2026
- PRESS-RELEASE reportMar 11, 2026
- 8-K reportFeb 24, 2026